• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Intensive Care Med . Respiratory indications for ECMO: focus on COVID-19

tetano

Editor, Senior Moderator
Intensive Care Med


. 2022 Aug 9.
doi: 10.1007/s00134-022-06815-w. Online ahead of print.
Respiratory indications for ECMO: focus on COVID-19


Alexander Supady[SUP] 1 2 [/SUP], Alain Combes[SUP] #[/SUP][SUP] 3 4 [/SUP], Ryan P Barbaro[SUP] 5 [/SUP], Luigi Camporota[SUP] 6 7 [/SUP], Rodrigo Diaz[SUP] 8 [/SUP], Eddy Fan[SUP] 9 10 11 [/SUP], Marco Giani[SUP] 12 [/SUP], Carol Hodgson[SUP] 13 14 15 16 [/SUP], Catherine L Hough[SUP] 17 [/SUP], Christian Karagiannidis[SUP] 18 [/SUP], Matthias Kochanek[SUP] 19 [/SUP], Ahmed A Rabie[SUP] 20 [/SUP], Jordi Riera[SUP] 21 [/SUP], Arthur S Slutsky[SUP] #[/SUP][SUP] 9 22 [/SUP], Daniel Brodie[SUP] #[/SUP][SUP] 23 24 [/SUP]



Affiliations

Abstract

Extracorporeal membrane oxygenation (ECMO) is increasingly being used for patients with severe respiratory failure and has received particular attention during the coronavirus disease 2019 (COVID-19) pandemic. Evidence from two key randomized controlled trials, a subsequent post hoc Bayesian analysis, and meta-analyses support the interpretation of a benefit of ECMO in combination with ultra-lung-protective ventilation for select patients with very severe forms of acute respiratory distress syndrome (ARDS). During the pandemic, new evidence has emerged helping to better define the role of ECMO for patients with COVID-19. Results from large cohorts suggest outcomes during the first wave of the pandemic were similar to those in non-COVID-19 cohorts. As the pandemic continued, mortality of patients supported with ECMO has increased. However, the precise reasons for this observation are unclear. Known risk factors for mortality in COVID-19 and non-COVID-19 patients are higher patient age, concomitant extra-pulmonary organ failures or malignancies, prolonged mechanical ventilation before ECMO, less experienced treatment teams and lower ECMO caseloads in the treating center. ECMO is a high resource-dependent support option; therefore, it should be used judiciously, and its availability may need to be constrained when resources are scarce. More evidence from high-quality research is required to better define the role and limitations of ECMO in patients with severe COVID-19.

Keywords: ARDS; Acute respiratory distress syndrome; COVID-19; ECMO; Extracorporeal circulation; Extracorporeal membrane oxygenation; Resource limitations; Respiratory failure.
 
Back
Top Bottom